EUCTR2011-000908-18-LT进行中（未招募）不适用
Treatment Protocol for young adults (18-45 years of age) with Acute Lymphoblastic Leukemia
Vilnius University Hospital Santariskiu Clinics0 个研究点目标入组 0 人开始时间: 2011年3月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Non B-ALL
- •2. Non Ph+ ALL
- •3. Age 18-45 years of age.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Bilineage ALL.
- •2. Pre-treatment with glucocorticosteroids or other antileukemic agents. Patients, who have been treated with systemic glucocorticosteroids or other anticancer agents (e.g. methotrexate or thiopurines) for more than a week prior to the diagnosis of ALL and initiation of antileukemic therapy, can be treated by the NOPHO ALL-2008 protocol and will be registered, but they cannot be included in the randomised trials.
- •3. Incomplete exploration for the risk group stratifying cytogenetic aberrations.
- •4. ALL predisposition syndromes. Patients with certain ALL-predisposing disorders (e.g. Down syndrome, Ataxia Telangiectasia) can be entered into the protocol with the amendments outlined in section 16, but can not be included in the randomised trials.
- •5. Previous cancer. Patients who have previously been treated for a malignant neoplasm can be treated by the NOPHO ALL-2008 protocol and will be registered, but they cannot be included in the randomised trials (see section 16). They will be treated according to the control arms of the protocol.
- •6. Intolerance to one or more anticancer agent.
- •7. Administration of additional chemotherapy during induction therapy for non-HR ALL. Patients with non-HR ALL, who at day 15 have a M3 bone marrow should not be given additional chemotherapy. If given, the patients will not be eligible for the SR-ALL treatment arm and the patient will not be eligible for randomisation.
- •8. Sexually active females not using contraception.
- •9. TPMT-deficiency (6MP-randomisation only).
- •10. DepoCyte during induction therapy (DepoCyte randomisation only)
研究者
相似试验
进行中（未招募）
不适用
Curative and palliative treatment of adults aged > 60 years with AML.A randomised trial by OSHO on the role of (1) early intensification {OSHO protocol} vs. common standard arm of German AML Intergroup Study, (2) allografting as consolidative immunotherapy vs. a second consolidation course in elderly patients,(3) prospective evaluation of the decision between curative and palliative treatment-intention. - AML 2004 OSHO #069Acute myelogenous leukemiaEUCTR2005-002833-10-ATGerman Competence network Acute and Chronic Leukemias” sponsored by Federal Ministry of Education a330
进行中（未招募）
1 期
Therapy for young and adult patients with early phase acute myeloid leukaemia, adjusted according to minimal residual disease and other risk factors for relapse.Acute myeloid leukaemiaMedDRA version: 14.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023809-36-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO237
招募中
3 期
Protocol for treatment of children and adolescents with acute myeloid leukemia 0-18 yearsbloodcancer10024324leukemiaNL-OMON55459Västra Götalandregionen, Queen Silvias Childrens and Adolescents Hospital150
终止
不适用
Developing Alternative Treatments for Young People with Depression: A study of transcranial alternating current stimulation (tACS).ACTRN12618001705279Monash University55
进行中（未招募）
不适用
Personalised treatment packages for adults with a learning disabilityMental and Behavioural DisordersIntellectual disabilityISRCTN71781827Camden and Islington NHS Foundation Trust410